NDASUBCUTANEOUSINJECTABLE
Approved
Aug 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
SUSTOL (granisetron) by Heron Therapeutics is serotonin 3 receptor antagonists [moa]. Approved for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting. First approved in 2016.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTOL (granisetron) is a subcutaneous, extended-release serotonin-3 receptor antagonist approved in 2016 for prevention of chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), and supportive care in oncology. It works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract. The product is currently at peak commercial lifecycle.
$88KPart D
PeakSUSTOL is in peak commercial phase with modest Medicare Part D penetration, indicating a mature, specialty-focused product with limited growth opportunity and smaller team structure.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Worked on SUSTOL at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.